Loading cancer entity…
Loading cancer entity…
Clinical trials
6,745 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,044)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05825625 | NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing | active not recruiting | Phase 2 | 35 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06219317 | Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC(ICARS) | active not recruiting | Phase 2 | 136 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK |
| 5 |
| Jun 23, 2026 |
| clinicaltrials |
| NCT03110978 | Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 140 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03476681 | Study of NEO-201 in Solid Tumors Expansion Cohorts | active not recruiting | Phase 1 / Phase 2 | 121 | Precision Biologics, IncINDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05773092 | A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC | active not recruiting | Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT04036682 | A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer(REZILIENT1) | active not recruiting | Phase 1 / Phase 2 | 284 | Cullinan Therapeutics Inc.INDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT05358249 | Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-03) | active not recruiting | Phase 1 / Phase 2 | 74 | Novartis PharmaceuticalsINDUSTRY | 8 | Jun 15, 2026 | clinicaltrials |
| NCT05565378 | A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer | active not recruiting | Phase 2 | 351 | GlaxoSmithKlineINDUSTRY | 22 | Jun 15, 2026 | clinicaltrials |
| NCT03137771 | Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 218 | NRG OncologyOTHER | 4 | Jun 8, 2026 | clinicaltrials |
| NCT04791839 | Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 30 | Washington University School of MedicineOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | active not recruiting | Phase 2 | 45 | Immune Oncology Research InstituteOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05633667 | Study of Novel Treatment Combinations in Patients With Lung Cancer(VELOCITY-Lung) | active not recruiting | Phase 2 | 192 | Gilead SciencesINDUSTRY | 8 | Jun 1, 2026 | clinicaltrials |
| NCT05676931 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer(EDGE-Lung) | active not recruiting | Phase 2 | 400 | Gilead SciencesINDUSTRY | 10 | Jun 1, 2026 | clinicaltrials |
| NCT04956640 | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | active not recruiting | Phase 1 / Phase 2 | 540 | Eli Lilly and CompanyINDUSTRY | 6 | May 29, 2026 | clinicaltrials |
| NCT06246110 | A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | active not recruiting | Phase 2 | 70 | Eikon TherapeuticsINDUSTRY | 1 | May 28, 2026 | clinicaltrials |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | active not recruiting | Phase 2 | 36 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03786692 | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC | active not recruiting | Phase 2 | 107 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT06015503 | A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)(KANNON) | active not recruiting | Phase 2 | 139 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT04015778 | A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China | active not recruiting | Phase 2 | 316 | Guangdong Association of Clinical TrialsOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05096663 | Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 / Phase 3 | 82 | SWOG Cancer Research NetworkNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06606847 | A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)(LADOGA) | active not recruiting | Phase 2 | 30 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06946797 | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)(CheckMate-1533) | active not recruiting | Phase 2 | 76 | Bristol-Myers SquibbINDUSTRY | 9 | May 14, 2026 | clinicaltrials |
| NCT04716946 | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy | active not recruiting | Phase 2 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03202940 | A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC | active not recruiting | Phase 1 / Phase 2 | 16 | Massachusetts General HospitalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05557591 | A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) | active not recruiting | Phase 2 | 51 | Regeneron PharmaceuticalsINDUSTRY | 7 | May 6, 2026 | clinicaltrials |
| NCT05012254 | Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases(NIVIPI-Brain) | active not recruiting | Phase 2 | 71 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05684276 | DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors(DUMAS) | active not recruiting | Phase 2 | 22 | Fundación GECPOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05491811 | Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation(EAGLE) | active not recruiting | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05195632 | Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer(OCEANII) | active not recruiting | Phase 2 | 63 | Pierre Fabre MedicamentINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT03838159 | NADIM II: Neo-Adjuvant Immunotherapy(NADIMII) | active not recruiting | Phase 2 | 90 | Fundación GECPOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT03122717 | Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 48 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT03586453 | Osimertinib In EGFR Mutant Lung Cancer | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06300424 | Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC(NEOVADE) | active not recruiting | Phase 2 | 32 | Guangdong Provincial People's HospitalOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05882513 | Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer | active not recruiting | Phase 2 | 36 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03909334 | Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 160 | Xiuning LeOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03157128 | A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)(LIBRETTO-001) | active not recruiting | Phase 1 / Phase 2 | 857 | Eli Lilly and CompanyINDUSTRY | 16 | Apr 16, 2026 | clinicaltrials |
| NCT03637816 | Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05635708 | A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 400 | BeiGeneINDUSTRY | 15 | Apr 15, 2026 | clinicaltrials |
| NCT06933329 | Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 73 | BicycleTx LimitedINDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT05553834 | PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung | active not recruiting | Phase 2 | 60 | Duke UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT03916627 | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients | active not recruiting | Phase 2 | 65 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT03377023 | Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04245514 | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 90 | Swiss Cancer InstituteOTHER | 2 | Apr 2, 2026 | clinicaltrials |
| NCT03433469 | Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery | active not recruiting | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT04268550 | Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) | active not recruiting | Phase 2 | 124 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 23, 2026 | clinicaltrials |
| NCT04699188 | Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation(KontRASt-01) | active not recruiting | Phase 1 / Phase 2 | 344 | Novartis PharmaceuticalsINDUSTRY | 16 | Mar 18, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 23, 2026source: clinicaltrials